We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MicroBeam Laser Microdissection System Developed for Live-Cell Applications

By Biotechdaily staff writers
Posted on 16 Apr 2007
A MicroBeam laser microdissection system is capable of simultaneous visualization and microdissection under multichannel fluorescence illumination and extended focus. More...
The system sets new standard for contamination-free specimen acquisition in the pharmaceutical industry and life science research.

Carl Zeiss (Welwyn Garden City, Hertfordshire, UK) has developed the Palm MicroBeam, which is built upon the Zeiss Axio Observer research grade inverted microscope. The Palm MicroBeam employs Palm's exclusive laser pressure catapulting (LPC) technology for contamination-free specimen acquisition.

Advanced fluorescence imaging is central to the characterization of biologic specimens, and the new system is ideally suited to live-cell applications. The Palm RoboSoftware may be used to generate single or multichannel images for up to five different wavelengths while the Axio Observer's high-performance filters enable up to 70% higher excitation intensities and allow the use of phase contrast and differential interference contrast (DIC) illumination. Higher excitation intensity also allows the Palm microbeam to reduce exposure times by up to 50%, which ensures minimum risk of bleaching and maximum protection for fragile living cells.

The Palm MicroBeam also overcomes depth of field limitations common to most other manufacturers' systems. The extended focus module within the Zeiss AxioVision software records a series of images at different focus positions through the specimen before automatically extracting the sharp details from each individual frame to calculate a final image that is contrast rich and sharp in every detail.

The combination of fluorescence imaging, extended focus, and non-contact, contamination-free isolation of tissue samples or living cells offers researchers the most extensive capabilities for the molecular analysis of DNA, RNA, proteins, and cells in the microdissection market, said Oliver Clarke, Palm product specialist at Zeiss UK. Combined with the Palm MicroBeam's automated image archiving, researchers can maintain sample custody at all times while operating with consummate precision, speed, versatility, and flexibility.

The Palm MicroBeam takes advantage of the Axio Observer platform by offering a flexible upgrade path through a wide range of options and modules, such as Zeiss AxioCam digital cameras, laser tweezers, and micromanipulation accessories. It is also fully integrated into the Zeiss AxioVision suite of imaging software.


Related Links:
Carl Zeiss

New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Hematology Consumables
Bioblood Devices
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: Pathlight combines WGS and dPCR to identify and longitudinally track large‑scale genomic changes, known as structural variants (photo courtesy of SAGA Diagnositcs)

Roche Affiliate Expands MRD Portfolio with SAGA Acquisition

Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.